EXTON, Pa., Sept. 13 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced that Vincent Milano, vice-president, chief operating officer and chief financial officer of ViroPharma, will present at the Maxim Group First Annual Growth Conference at 2:30 P.M. ET on Thursday, September 20, 2007. The conference is being held at the Grand Hyatt in New York.
ViroPharma’s presentation will be webcast live for investors through http://www.viropharma.com and available through October 4, 2007.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company’s website at http://www.viropharma.com.
ViroPharma Incorporated
CONTACT: William C. Roberts, Senior Director, Corporate Communications,+1-610-321-6288, or Robert A. Doody, Manager, Corporate Communications,+1-610-321-6290, both of ViroPharma Incorporated
